Johnson & Johnson’s CARVYKTI Growth Falls to 57.4% on $600M Sales
JNJ•CARVYKTI recorded $600 million in quarterly sales with year-over-year growth of 57.4%, down from 63.2% last quarter, signaling a subtle warning. This deceleration puts pressure on Johnson & Johnson’s path to $100 billion revenue and double-digit growth by the end of the decade.
1. CARVYKTI Growth Trajectory
CARVYKTI generated approximately $600 million in sales during the most recent quarter, representing 57.4% year-over-year growth. This marks a deceleration from the prior quarter’s 63.2% increase, the first notable slowdown in its early commercial ramp.
2. Implications for Revenue Ambitions
Johnson & Johnson aims to reach $100 billion in annual revenue and achieve double-digit growth by the end of the decade. The company’s long-term outlook hinges on sustained acceleration from CARVYKTI alongside other pipeline therapies.
3. Valuation Pressure
The stock trades at a price-to-sales multiple of 5.9, near its 10-year high of 6.1, suggesting the market has fully priced in strong performance from new products. Any further deceleration in CARVYKTI’s growth could prompt investors to reassess that premium valuation.
4. Key Watchpoints
Investors should monitor upcoming quarterly growth percentages for CARVYKTI rather than absolute sales figures. Continued slowing could signal challenges in scaling this cell therapy to a multi-billion-dollar franchise and strain overall growth expectations.
